Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company

Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

May 16, 2017 1:00 AM EDT

Vifor Pharma Ltd. / Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

                                               
    --   Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Use in its Dialysis Facilities and Invests $50 Million in Akebia at a Premium --
         ... More

Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

May 15, 2017 4:05 PM EDT

Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Use in its Dialysis Facilities and Invests $50 Million in Akebia at a Premium

Additional Funds Support Vadadustat Global Development Program to Data

Akebia to Host Conference Call at 4:30 p.m. Eastern Time Today

CAMBRIDGE, Mass. & ZURICH--(BUSINESS WIRE)--... More